Organization: Health Canada
Year: 2023
Month: July
Request Number: A-2017-000315
Request Summary: The most current Canadian Risk Management Plan (RMP) or Canadian Addendum to the RMP and Canadian RMP review report for Avastin (Bevacizumab) by Hoffmann-La Roche Limited, Drug Identification Number (DIN): 02270994
Disposition: Disclosed in part
Number of pages: 392